PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]

  • Awaiting development
  • GID-TA11325
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of PXT3003 within its marketing authorisation for treating Charcot-Marie-Tooth disease ID1439